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Abstract 
Background: The use of lymph node sampling during staging procedures in clinical early stage 
mucinous ovarian carcinoma (MOC) is an ongoing matter of debate. The incidence of lymph node 
metastases in MOC in relation to tumor grade is unknown. If lymph node metastases in clinical 
early stage G1 MOC would be non-existent, lymph node sampling might be safely omitted. We 
aimed to determine the incidence of lymph node metastases in clinical early stage MOC per tumor 
grade. 
 
Materials & Methods: Histology report summaries from patients with MOC between 2002 and 2012 
were obtained from the Dutch National Pathology Registry (PALGA). All reports were reviewed to 
confirm diagnosis, tumor grade and presence of lymph node metastases. Clinical data, surgery 
reports and radiology reports of patients with lymphadenopathy, were retrieved from hospital files. 
 
Results: In the Netherlands, 915 patients with MOC were diagnosed and 426 underwent lymph 
node sampling. The other 489 patients had either cytoreductive surgery or were staged without 
lymph node sampling. In 7 patients, lymph node metastases were discovered by lymph node sam-
pling. In 4 of 190 (2.1%) G1 MOC patients, lymph node metastases were present, compared to 1 
of 115 (0.9%) G2 MOC patients and 3 of 22 (13.6%) G3 MOC patients. Tumor grade was not spec-
ified in 99 patients. No recurrence-free survival benefit from lymph node sampling was observed in 
patients with clinical early stage MOC. 
 
Conclusion: These data indicate that lymph node sampling can be safely omitted in patients with 
G1 and G2 MOC without clinical suspicion of metastases.  
 
 
Introduction 
Epithelial ovarian cancer (EOC) is the cancer with the highest mortality of all gynecological 
malignancies. In the Netherlands, each year approximately 1300 patients are diagnosed with this 
disease. EOC is a term that encompasses serous, mucinous, seromucinous, endometrioid, 
clearcell and undifferentiated adenocarcinomas. The majority of patients with EOC are diagnosed 
with serous adenocarcinoma. Mucinous ovarian carcinoma (MOC) is a relatively rare subgroup of 
these ovarian malignancies. Due to revised criteria for the diagnosis of MOC, its incidence has 
even further declined over the past decades and is now estimated to be 3-5% of all EOC [1, 2].  
Patients with MOC often present with a large unilateral ovarian mass without metastasized 
disease. In these patients, prognosis is relatively good with a 5-year disease free survival of 90.8% 
[3]. However, the course of advanced stage MOC is less favorable with fast progression and low 
response rates to chemotherapy. Seromucinous carcinoma is a rare ovarian malignancy that has 
been identified as a separate entity in the revised World Health Organization Classification of 
Tumors of the Female Reproductive Organs [4]. This tumor type is characterized by an admixture 
of serous, mucinous and endometrioid cell types. Moreover, patients with a seromucinous 
carcinoma are primarily diagnosed with disease confined to the ovary. Therefore, their prognosis is 
relatively good [5]. 
In patients with clinical early stage EOC, a complete staging procedure including lymph 
node sampling is recommended to exclude the presence of microscopic metastases. During the 
staging procedure, bilateral salpingo-oophorectomy, hysterectomy and (infracolic) omentectomy 
are performed and peritoneal biopsies are taken. Furthermore, a lymph node sampling of at least 
10 lymph nodes from the para-aortic and pelvic region is advised. In many patients with MOC, this 
procedure is also performed; although, several studies have demonstrated a low incidence of 
lymph node metastases of 0.0-6.7% [6, 7]. 
Apart from histological classification, EOC can be divided by tumor grade. Internationally, 
the Silverberg/Shimizu criteria, by which the tumor is rated for dominating architectural pattern, 
nuclear atypia and mitotic activity rate, are often used. However, a two-tier system dividing the 
tumor into either low or high-grade tumors is preferred by more and more pathologists [8, 9]. These 
systems are primarily developed for serous and endometrioid carcinomas, but are less applicable 
to MOC because of their overall low-grade architectural appearance. No histological grading 
system has been universally accepted for MOC. As a result, most pathologists use the three-tier 
grading system for MOC, in the absence of a better alternative. Histological grading is important 
because of its prognostic relation, but can also influence the choice of treatment. In several 
histotypes of EOC, low-grade tumors have a more indolent course of disease with a favorable 
progression-free and overall survival, compared to high-grade tumors [10]. It can be expected that 
patients with low-grade tumors demonstrate a much lower incidence of lymph node metastases 
compared to high-grade tumors. Indeed, Kleppe et al. demonstrated that 4.0% of serous and 
endometrioid EOC patients with grade (G) 1 tumors and apparent FIGO stages I and II disease 
had lymph node metastases, compared to 20.0% in G3 tumors. [6]. In MOC, the correlation 
between tumor grade and lymph node metastases is unknown. We hypothesized that lymph node 
metastases in clinical early stage G1 MOC have a low incidence or are non-existent. The aim of 
this study was to evaluate the need for a complete staging procedure, including lymph node 
sampling in patients with clinical early stage MOC of different tumor grades.  
 
Materials and methods 
Patient selection 
The Dutch Pathology Registry (PALGA) [11], a nationwide network and registry that records all 
histopathology and cytopathology since 1991, was searched after approval of the privacy 
committee of PALGA. All patients diagnosed with MOC between January 2002 and December 
2012 were selected based on pathology reports comprising the terms: “ovary” OR “tube”, AND 
“mucinous carcinoma” OR “mucinous adenocarcinoma” OR “mucin”. The pathology reports during 
treatment of MOC, as well as all reports before and after treatment with a follow-up period of at 
least 24 months, were obtained. A database of 18,465 pathology reports from a total of 1828 
patients was built. For privacy reasons, all patients from the registry are itemized by a specific 
PALGA-code. Under this code, excerpts containing anonymized pathology reports, dates of tissue 
collection and age at time of tissue collection are registered. Researchers had no access to patient 
names or private information. Therefore, no patient informed consent and no additional approval of 
the Institutional Review Board was required. 
All excerpts were initially scrutinized by the principal author (JVB). Ovarian tumors with a 
histological diagnosis other than MOC, tumors with insufficient criteria of invasive malignancy (i.e. 
borderline tumor, carcinoma in situ), ovarian metastasis of tumors from a different primary origin 
and reports with inconclusive data were excluded (for exclusion criteria, see Figure 1). In case of 
ambiguity concerning diagnosis, reports were discussed with an expert in gynecologic pathology 
(KVV). FIGO stage was determined for each tumor. Of each case, the primary diagnosis and 
official  revision of histopathology were documented. 
Seromucinous, endocervical-type mucinous and Müllerian mucinous carcinomas or mixed 
cell types with a mixed endometrioid or serous and mucinous aspect were collectively grouped as 
seromucinous carcinoma, according to the new WHO-guidelines [12]. 
Information including clinical data, surgery reports, radiology reports and follow-up data of 
all patients with lymph node metastases was retrieved from the hospital files via an intermediate 
procedure of PALGA. Anonymized clinical data and patient characteristics were requested from the 
treating physicians to maintain absolute privacy of the patient. No histology was required for this 
study. Therefore, no informed consent was needed to collect these additional clinical data.  
 
Statistical analyses 
The incidence rate of lymph node metastases in patients with MOC was calculated by dividing the 
patients with metastases by the total number of patients. Additionally, to gain insight into changes 
in incidence of MOC over the study period, incidence rates per year and per 100,000 women were 
calculated with the average yearly female population numbers in the Netherlands [13]. Recurrence-
free survival (RFS) was calculated for all patients that had recurrent disease, confirmed by 
histological examination. Normally distributed data was described as mean values with standard 
deviations. In case data was not normally distributed, median values and ranges (0-100%) were 
reported. Statistical analyses were performed using IBM SPSS (Statistical Package for the Social 
Sciences) version 22.0 (SPSS Inc., Chicago, Illinois). The two-sided Chi-square test was used for 
categorical variables and the student’s t-test was used to evaluate differences in normally 
distributed, continuous variables. Kaplan-Meier survival curves were generated for FIGO stage I 
patients with and without lymph node sampling to determine RFS. Patients that were lost to follow-
up, were right-censored in the survival curves. Equality of RFS between these groups was 
calculated with Log Rank (Mantel-Cox) tests. 
 
Results 
Mucinous ovarian cancer 
From a search of PALGA, the Dutch Pathology Registry, a total of 1828 patients with possible 
MOC were identified between January 2002 and December 2012. After detailed examination of the 
reports from the PALGA registry, 803 patients were excluded for reasons such as ovarian 
metastases of a different primary origin or lack of malignancy, leaving 1025 patients eligible for our 
study (Figure 1). Of these 1025, patients diagnosed with a primary MOC totalled 915 individuals 
and 110 patients with a seromucinous carcinoma. Clinical characteristics of these patients with 
MOC are shown in Table 1.  
The majority of patients were diagnosed with a G1 or G2 MOC. In the total group of patients 
with MOC, 17 (1.9%) patients were diagnosed with lymph node metastases. In 9 patients with 
nodal disease, lymph node metastases were removed during cytoreductive surgery for advanced 
disease or after histological biopsy of an enlarged lymph node. A significantly lower incidence of 
lymph node metastases was seen in G1 MOC (1.4%) compared to G3 MOC (5.7%, p = 0.03). No 
significant difference was seen between G1 and G2 MOC (1.4% vs. 2.6%, p = 0.35), or between 
G2 and G3 MOC (p = 0.19) (Table 1). During the 11 years included in this study, the incidence 
rates of MOC per 100,000 Dutch women per year declined (Figure 2). 
To understand whether tumor grade influences the chance of lymph node metastases in 
clinical early stage MOC, we focussed on the patients who received staging procedures (Table 2). 
Complete staging procedures including lymph node sampling, were performed in 426 patients, 
revealing 8 patients with lymph nodes metastases. Patients with G1 and G2 disease showed 
significantly less lymph node metastases compared to G3 MOC (G1 versus G3 p = 0.03; G2 
versus G3 p = 0.01). These data indicate that lymph node metastases in clinical early stage MOC 
of G1 and G2 disease are rare. 
To examine whether the patients with lymph node metastases (n=8) had apparent evidence 
of lymphadenopathy on preoperative radiological imaging or during the staging procedures, we 
examined the clinical data of these patients (Table 3). Interestingly, in 5 out of 8 (62.3%) of patients 
with metastases identified during staging lymph node sampling, enlarged lymph nodes were 
already present on radiological examination or enlarged by palpation during the staging 
procedures. Thus, in patients with G1 MOC without clinical suspicion of metastatic disease, only 2 
(95%CI 0.13-3.75%) patients had unexpected lymph node metastases. Patients with G2 MOC 
without signs of clinical metastases had no lymph node metastases found with staging procedures 
(95%CI 0-0.03%). However, 4.5% (95%CI 0.12-22.84%) of patients with G3 MOC, without pre-
operative evidence of metastatic disease in the lymph nodes were shown to have (microscopic) 
lymphadenopathy. 
Next, to evaluate whether tumor grade is correlated with RFS, Kaplan-Meier survival 
analyses were performed of all FIGO stage I patients with MOC (Figure 3a). A more favorable RFS 
was observed for patients with G1 and G2 MOC than for those with G3 MOC (p < 0.0001).  
In 6.6% of patients with G1 MOC with FIGO stage I, recurrent disease was diagnosed after 
a median of 16 months (range 5-39), whereas 11.0% of patients with G2 MOC and 33.3% of 
patients with G3 developed recurrent disease after 15.5 and 8.0 months, respectively. RFS of 
clinical FIGO stage I patients without lymph node sampling and patients who underwent staging 
lymph node sampling were comparable for G1, G2 and G3 (Figure 3b). Table 3 demonstrates 
numbers of patients with recurrent disease and RFS per tumor grade. Taken together, these results 
demonstrate that performing lymph node sampling in the absence of clinical evidence of 
metastases does not favor RFS.  
 
Seromucinous ovarian cancer 
Of the 1828 patients who presented with EOC between January 2002 and December 2012, 110 
patients were diagnosed with a seromucinous (or endocervical-type mucinous) carcinoma (Figure 
1). During this time, the incidence of seromucinous carcinoma was stable (Figure 2). The 
characteristics of these patients are presented in Table 4. The mean age of this cohort was 56.1 
years and there was no difference in age when the group was subdivided by grade. Most patients 
(58.3%) were diagnosed with G1 disease. Among the entire seromucinous carcinoma cohort, 5 
(4.5%) patients had lymph node metastases. Strikingly, none of these lymph node metastases 
were found in patients with G1 seromucinous carcinoma. In 3 (60%) patients with 
lymphadenopathy, axillar or supraclavicular lymph node metastases were found, which was not 
found in the MOC patients.  Staging procedures were performed in 46 out of 110 patients, but did 
not reveal any additional lymph node metastases. Recurrent disease occurred in 25 patients 
(22.7%) with seromucinous carcinoma. In patients with FIGO stage I disease with G1, G2 and G3 
seromucinous tumors, recurrent disease occurred in 4 (12.9%), 3 (16.7%) and 2 (50%) patients, 
respectively. In conclusion, lymph node metastases in G1 seromucinous carcinoma could not be 
found. However, the number of patients that received lymph node samplings in the present study is 
too small to draw solid conclusions from these results.  
 
Discussion 
The current study shows that the incidence of lymph node metastases in patients with clinical early 
stage G1 or G2 MOC is very low. In case of absence of enlarged lymph nodes on radiological 
examination or on palpation during staging procedures, only 0.7% of the patients with G1 and G2 
MOC together had lymph node metastases. In addition, no RFS benefit from lymph node sampling 
was observed in patients with clinical FIGO stage I MOC. 
This is the first study that reports lymph node metastases in MOC per tumor grade. 
Previous studies demonstrated a low overall incidence of lymph node metastases in clinical early 
stage MOC (0.0-6.7%) [6, 7]. Our study demonstrates that G3 MOC is associated with a higher 
incidence of lymph node metastases discovered during staging procedures, compared to G1 and 
G2 MOC. Staging lymph node samplings were performed in only 22 patients with G3 MOC. 
However, our findings suggests that G3 MOC has another clinical behavior leading to a more 
advanced stage disease at presentation and a higher incidence of lymph node metastases. 
Patients with G1 and G2 MOC presented with a similar course of disease, with equal FIGO stages 
at diagnosis, equal incidences of lymph node metastases and comparable RFS. This tumor grade 
specific behavior can also be seen in other histotypes of EOC, such as low grade and high grade 
serous carcinoma [14, 15]. Therefore, different tumor grades of MOC should not be regarded as 
one group, as G1 and G2 MOC represent a different course of disease than G3 MOC. The 
differences in clinical behavior may be explained by differences in genetic drivers. Several mutated 
genes have been identified for MOC, including KRAS, BRAF, CDKN2A and TP53 genes [16-19]. 
Recently, a study of Ryland et al. investigated the variances of the genomic landscapes between 
the tumor grades of MOC [16]. However, in this study, demonstrating evident differences between 
the tumor grades was hindered by the heterogeneity of MOC and the small study populations.   
Defining tumor grade in MOC remains a matter of debate amongst pathologists, as the 
current classification system is suboptimal for MOC and a specific grading system does not exist. A 
new classification system of grading MOC is needed to optimize separating patients with poor 
prognosis from patients with more favorable prognosis. Our results implicate that possibly a two-
tier classification system should be developed in which G1, G2 and G3 MOC are subdivided into a 
low grade and a high grade group. Identification of the molecular differences between tumor 
grades of MOC will also create a valuable contribution to the distinction of the different prognostic 
groups.  
Lymph node sampling in early stage EOC has been the subject of debate for the past 
years. Previously, some studies demonstrated a survival benefit for patients with early stage EOC 
who received complete staging procedures [19, 20]. However, in these studies, different histotypes 
of EOC are taken together and none of these studies investigated MOC with focus on its separate 
tumor grades. In The Netherlands, clear guidelines are formulated concerning staging procedures 
for clinical early stage EOC. Herein, a complete staging procedure is recommended with dissection 
of a minimum of 10 lymph nodes. In our study, only 64% of the patients with clinically early stage 
disease had a staging procedure with lymph node sampling. This number reflects the ongoing 
ambiguity amongst gynecologists concerning the necessity to perform a lymph node sampling in 
this group of patients. 
In the current literature, only few studies with small numbers of included patients have 
investigated the behavior and morphology of the seromucinous carcinoma [20-22]. This is the first 
study reporting data of a large cohort with a total of 110 seromucinous carcinomas. This relatively 
uncommon EOC tends to behave different in comparison to MOC. Lymph node metastases were 
more common than in MOC, but did not occur in G1 seromucinous carcinoma. Also, in 60% of the 
patients with lymph node metastases, tumor involvement of axillary or supraclavicular lymph nodes 
was seen, which did not occur in the MOC group. Extraperitoneal lymph node metastases of high 
grade serous carcinoma at time of presentation has been described in the literature [23]. This 
suggests that G2 and G3 seromucinous carcinomas resemble a metastases pattern similar to that 
of a high-grade serous carcinoma. Future studies must be performed to demonstrate possible 
similarities in genetic drivers of these tumors. Interestingly, patients with a seromucinous 
carcinoma had no lymph node metastases found with staging lymph node sampling. However, the 
number of patients that received a lymph node sampling during staging procedures was small. 
Therefore, no robust conclusions can be drawn for these patients with a clinical early stage 
seromucinous carcinoma. These findings may be the basis for future studies in which multicentre 
collaboration is particularly needed to achieve sufficient study populations. For all tumor grades, 
recurrent disease appeared to occur more frequently in FIGO stage I patients with a seromucinous 
carcinoma than patients with MOC (G1 12.9%, G2 16.7%, G3 50.0%). These results are consistent 
with the new WHO Classification of Tumors of the Female Reproductive Organs of 2014 [12], in 
which seromucinous carcinomas are included as a separate entity, rather than as a variant of 
MOC.  
A limitation of our study is that the incidence of recurrent disease was based on 
histopathological examination. This might have led to an underestimation of the incidences of 
recurrences. An obvious recurrence diagnosed with clinical or radiological examination might, in 
some cases, have been treated without histopathological confirmation.  
A second limitation is that small sized, non-suspicious lymph nodes can still contain 
microscopic metastatic disease. The chance of not finding small lesions is higher in the patients 
without lymph node sampling. In our study, the number of removed lymph nodes was unknown for 
39.0% of patients who received lymph node samplings. In 39.2% of all staged patients, a minimum 
of 10 lymph nodes was resected, which number is supposed to reflect the lymph node status 
accurately in FIGO stage I patients [24, 25]. However, RFS was equal for both the groups with and 
without lymph node sampling. The differences between the grades of MOC are unlikely to change 
because of this.  
We based our results on existing pathology and radiology reports and no additional revision 
was performed to confirm diagnosis and absence of lymphadenopathy. Yet, our results showed 
that in 34.9% of all cases, official histopathological revision had already been performed. 
Furthermore, patients with MOC are treated in a third-line institute, where histopathological revision 
by an expert in gynecologic pathology is part of the standard care. However, in 24.3% of all 
diagnosed MOC, tumor grade was not specified in the pathology reports by pathologists. Our 
results emphasize the importance of a precise histopathological designation in combination with 
specification of tumor grade and should therefore be performed by a gynaecological oriented 
pathologist. 
Unfortunately, we had no information concerning the administration of adjuvant 
chemotherapy. Although for G3 MOC or for non-optimally staged patients, administration of 
adjuvant chemotherapy may have been considered, it is unlikely that completely staged patients 
with FIGO stage I with G1 or G2 MOC have received chemotherapy. In addition, the poor 
chemosensitivity of MOC [26, 27] implicates that administration of adjuvant systemic treatment 
may have only minimal effect on the outcome of FIGO stage I MOC. 
In conclusion, our results imply that staging lymph node sampling can be safely omitted in 
G1 and G2 MOC. Omitting this procedure could have a positive effect on surgery-related complica-
tions, total blood loss and operating time [28]. However, a well-trained and experienced surgeon is 
a prerequisite for the optimal assessment of enlarged lymph nodes during surgery and the subse-
quent decision whether lymph node sampling should be performed or not.  
 
Figure 1. Flow chart of patient selection. NEED MORE DESCRIPTION OF WHAT YOU DID HERE 
 
 
 
Figure 2. Incidence of mucinous and seromucinous ovarian cancer in The Netherlands between January 
2002 and December 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of total group of 915 patients with MOC per tumor grade.   
Variable All MOC      
  G1 MOC G2 MOC G3 MOC 
Grade 
unspecified 
P-value 
n (%) 915 (100) 369 (40.3) 229 (25.0) 88 (9.6) 229 (25.0)  
Mean age (yrs 
(95%CI)) 
55.7 (54.7-56.7) 54.0 (52.4-55.6) 55.4 (53.4-57.5) 56.8 (53.6-60.0) 58.1 (56.1-60.0) 0.02a 
FIGO stage (n (%)) 
     I 
     II 
     III 
     IV 
     Unknown 
 
623 
46 
159 
29 
58 
 
286 (77.5) 
17 (4.6) 
42 (11.4) 
4 (1.1) 
20 (5.4) 
 
162 (70.7) 
8 (3.5) 
41 (17.9) 
8 (3.5) 
10 (4.4) 
 
 
26 (29.5) 
14 (15.9) 
32 (36.4) 
9 (10.2) 
7 (8.0) 
 
 
149 (65.1) 
7 (3.1) 
44 (19.2) 
8 (3.5) 
21 (9.2) 
0.04b 
Histopathological 
revision (n (%)) 
319 (34.9) 151 (40.9) 75 (32.8) 30 (34.1) 63 (27.5) 0.01c 
Tumor 
characteristics  
(n (%)) 
    Intestinal type 
    Infiltrative growth   
    Expansive growth  
 
 
84 (9.2) 
6 (0.7) 
42 (4.6) 
 
38 (10.3) 
3 (0.8) 
15 (4.1) 
 
20 (8.7) 
1 (0.4) 
8 (3.5) 
 
4 (4.5) 
0 (0) 
4 (4.5) 
 
22 (9.6) 
2 (0.9) 
15 (6.6) 
 
 
0.40c 
 
0.09b 
 
LNM (n (%)) 
     Yes 
     No 
     Unknown 
 
17 (1.9) 
428 (46.8) 
470 (51.4) 
 
5 (1.4) 
188 (50.9) 
176 (47.7) 
 
6 (2.6) 
117 (51.1) 
106 (46.3) 
 
5 (5.7) 
21 (23.9) 
62 (70.5) 
 
1 (0.4) 
102 (44.5) 
126 (55.0) 
 
<0.001c 
 
 
aOne-Way ANOVA test 
bLinear-by-Linear Association test 
cPearson Chi-Square test  
LNM = Lymph node metastases 
 
 
 
 
 
 
 
 
 
 
Table 2. Staging lymph node sampling performed in 426 patients with clinical early stage MOC per tumor grade. 
Variable 
G1 MOC 
n (%) 
G2 MOC 
n (%) 
G3 MOC 
n (%) 
MOC 
Grade unspecified 
n (%) 
Number of patients 190 (44.6) 115 (27.0) 22 (5.3) 99 (23.2) 
LNM  4 (2.1) 1 (0.9) 3 (13.6) 0  
Radiological examination in patients 
with LNM  
        Patients with normal lymph nodes 
        Patients with enlarged lymph nodes 
        Unknown 
 
 
3 (75) 
0  
1 (25) 
 
 
0 
1 (100) 
0 
 
 
2 (66.7) 
0  
1 (33.3) 
- 
Observations during surgery in 
patients with LNM  
        Patients with normal lymph nodes 
        Patients with enlarged lymph nodes 
 
 
2 (50) 
2 (50) 
 
 
1 (100) 
0 
 
 
1 (33.3) 
2 (66.7) 
- 
LNM = Lymph node metastases 
 
 
 
Table 3. Differences between FIGO stage I patients with complete staging procedure and incomplete staging  
Variable 
FIGO stage I with 
complete staging* 
n=401 
Clinical FIGO stage I 
incomplete staging** 
n=222 
P-value 
Tumor grade (n (%)) 
     G1 
     G2 
     G3 
     Grade unspecified 
 
178 (44.4) 
112 (27.9) 
15 (3.7) 
96 (23.9) 
 
108 (48.6) 
50 (22.5) 
11 (5.0) 
53 (23.9) 
 
Recurrent disease (n (%)) 
     G1 
     G2 
     G3 
     Grade unspecified 
 
9 (5.1) 
11 (9.8) 
5 (33.3) 
8 (8.3) 
 
10 (9.3) 
4 (8.0) 
5 (36.4) 
6 (11.3) 
 
0.22a 
0.48a 
0.60a 
0.37a 
Median RFS in months (range) 
     G1 
     G2 
     G3 
     Grade unspecified 
 
21.0 (5-39) 
14.0 (5-46) 
8.0 (6-24) 
14.0 (4-51) 
 
27.0 (19-146) 
11.5 (9-46) 
21.5 (7-107) 
17.0 (9-68) 
 
0.35b 
0.89b 
0.79b 
0.39b 
*Staging procedure including lymph node sampling with tumor-negative lymph nodes 
**Staging procedure without lymph node sampling  
LNM = Lymph node metastases 
RFS = Recurrence free survival 
 aOne-sided Fisher’s Exact Test 
bLog Rank Mantel Cox Test 
 
Table 4. Characteristics of 110 patients with seromucinous ovarian carcinoma per tumor grade 
Variable 
All 
Seromucinous 
carcinoma 
     
  
Seromucinous 
carcinoma 
G1 
Seromucinous 
carcinoma 
G2 
Seromucinous 
carcinoma 
G3 
Seromucinous 
carcinoma 
Grade 
unspecified 
P-value 
n (%) 110 (100) 43 (39.1) 30 (27.3) 16 (14.5) 21 (19.1)  
Mean age (yrs 
(95%CI))  
56.1 (53.5-
58.8) 
58.3 (54.0-
62.5) 
58.3 (53.4-
63.1) 
51.6 (43.6-
59.6) 
52.1 (45.4-
58.7) 
0.17a 
FIGO stage (n 
(%)) 
     I 
     II 
     III 
     IV 
     Unknown 
 
 
66 (60.0) 
13 (11.8) 
21 (19.1) 
7 (6.4) 
3 (2.7) 
 
 
31 (72.1) 
4 (9.3) 
4 (9.3) 
2 (4.7) 
2 (4.7) 
 
 
18 (60.0) 
5 (16.7) 
5 (16.7) 
2 (6.7) 
0 (0) 
 
 
4 (25.0) 
2 (12.5) 
7 (43.8) 
3 (18.8) 
0 (0) 
 
 
13 (61.9) 
2 (9.5) 
5 (23.8) 
0 (0) 
1 (4.8) 
0.56b 
Histopathological 
revision    
(n (%))  
38 (34.5) 21 (48.8) 8 (26.7) 4 (25.0) 5 (23.8) 0.09c 
LNM (n (%)) 
     Yes 
     No 
     Unknown 
 
5 (4.5) 
48 (43.6) 
57 (51.8) 
 
0 (0) 
20 (46.5) 
23 (53.5) 
 
2 (6.7) 
16 (53.3) 
12 (40.0) 
 
2 (12.5) 
4 (25.0) 
10 (62.5) 
 
1 (4.8) 
8 (38.1) 
12 (57.1) 
0.10c 
 
Staging lymph 
node sampling 
(n (%)) 
46 (41.8) 19 (44.2) 16 (53.3) 3 (18.8) 8 (38.1)   
Recurrent 
disease (n (%)) 
25 (22.7) 7 (16.3) 9 (30.0) 4 (25.0) 5 (23.8) 0.58c 
aOne-Way ANOVA test 
bLinear-by-Linear Association test 
cPearson Chi-Square test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a. Kaplan Meijer curves of survival of all FIGO stage I patients with MOC per tumor grade.  
 
 
 
 
Survival curves of all patients with clinically FIGO stage I MOC, with a favorable RFS for G1 MOC and a 
poorer RFS for G3 MOC (Log Rank 18.30, p < 0.0001).  
 
 
 
 
 
 
Figure 4b. Kaplan Meijer curves demonstrating RFS of patients with FIGO stage I disease,  G1 and G2 
MOC, with and without lymph node sampling.  
 
 
 
 
 
Survival curves are demonstrated of patients with G1 and G2 combined, who received staging procedures 
either with or without lymph node sampling. No survival benefit was observed in the patients who had lymph 
node sampling (Log Rank 0.183, p = 0.67).  
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